

Northern Minnesota-Wisconsin Area Retail Clerks Fringe Benefit Funds

2002 London Road – Suite 300
Duluth, MN 55812

Wilson-McShane Corporation
Fund Administrators

Telephone: (218) 728-4231
Fax: (218) 728-4773
Toll Free: (877) 752-3863

SUMMARY OF MATERIAL MODIFICATIONS

The Board of Trustees has amended the Plan Document and Summary Plan Description (“SPD”). This notice summarizes the changes to the SPD and the effective dates of the changes.

Effective February 1, 2025

1. Coverage of GLP-1 drugs is limited to treatment for diabetes.

For purposes of this limitation, “GLP-1 drugs” means prescription drugs that are approved by the FDA for any indication, now or in the future, and that contain glucagon-like peptide-1 receptor agonists. Examples of GLP-1 drugs include, without limitation:

- Brand drugs Wegovy, Saxenda, Zepbound, Ozempic, Victoza, Trulicity, Mounjaro, Rybelsus, Byetta, Bydureon Bcise, Xultophy, and Soliqua; and,
- Compounded drugs containing glucagon-like peptide-1 receptor agonists (e.g., semaglutide, tirzatepide, dulaglutide, liraglutide, exenatide, or lixisenatide).

If you are prescribed a GLP-1 drug for treatment of obesity, heart disease, sleep apnea, alcohol dependence, or any other disease or condition (except diabetes), the prescription will not be covered.

Please retain this notice with your current copy of the Plan Document and Summary Plan Description. If you have any questions about the Plan, contact the Fund Office at (218) 728-4231 or (877) 752-3863. Except as expressly described in this SMM, the terms of the SPD are unchanged. This Summary of Material Modification provides only highlights of recent changes to the Plan Document and Summary Plan Description. This SMM will be disregarded for purposes of administering the SPD. Contact the Fund Office for a copy of the SPD and all amendments. The Trustees reserve the right to amend, modify or terminate the SPD at any time.

REMINDER: If your address, telephone number, or email address has changed, or if you have married, divorced, had a child, or had a similar event, contact the Fund Office at (218) 728-4231 or (877) 752-3863 to update your contact, dependent, or beneficiary information.